Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Enhanced MRI

Sep 2006
Although oncologists regularly use MRI to fulfil cancer-imaging needs, they tend to supplement it with other methods, such as spectroscopy. Many such techniques have deepened and broadened MRI application, but they need further development or investigation via multicenter clinical trials. With time, the true power of MRI may result from its physiologic and functional abilities, rather than its simply volumetric depictions, according to A. Gregory Sorensen of Massachusetts General Hospital in Boston.

In a review of the uses of MRI in oncology, the author observes that every magnetic resonance imager contains a spectrometer that can sense spectral variations among tissues, and hardware and software modifications can allow the device to detect several chemical and imaging signatures of cancer or chemotherapeutic agents. For example, researchers have used magnetic resonance spectrometry to detect elevated choline — a correlate of breast cancer — and to monitor the delivery of chemotherapeutic agents that contain fluorine.

For the brain, doctors have used a type of MRI called dynamic susceptibility contrast to measure blood volume and flow rate because these factors tend to increase in tumors.

By detecting the microscopic movement of water, diffusion MRI can show tissue damage. Doctors can use this technique to monitor the effects of chemotherapy because diffusion rates change dramatically as tissue dies. More complex modifications of this technique can show tumor microarchitecture, which can help doctors plan treatment.

Although physicians have used some of the aforementioned methods as a primary screen for cancer or to judge cancer treatment, some newer techniques have not yet entered the clinic. For example, scientists are examining the ability of MRI to both display differences in blood vessel morphology — an indicator of malignancy — and to make measurements of tissue elasticity because tumors are often firmer than surrounding tissue. Because MRI cannot normally detect its weak signal, work with hyperpolarized carbon is underway. In addition, researchers are exploring combined MRI-PET scanners. (Journal of Clinical Oncology, July 10, 2006, pp. 3274-3281.)

BiophotonicsenergyFrom The Journalsspectroscopy

Terms & Conditions Privacy Policy About Us Contact Us
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x Subscribe to BioPhotonics magazine - FREE!
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.